ArticleJournal of neurology2022

Early B cells repopulation in multiple sclerosis patients treated with rituximab is not predictive of a risk of relapse or clinical progression.

Guillaume Dorcet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.